X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
ENV105 (carotuximab) is a endoglin inhibitor which is being evaluated in phase 2 clinical trials in combination with apalutamide for the treatment of castrate-resistant prostate cancer.
Lead Product(s): Carotuximab,Apalutamide
Therapeutic Area: Oncology Product Name: ENV105
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2024
Details:
ENV105 (carotuximab) is a novel ENG inhibitor monoclonal antibody. It is currently being evaluated in phase 1 clinical trials in combination with osimertinib for the treatment of non-small cell lung cancer.
Lead Product(s): Carotuximab,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: ENV105
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
The companies said DE-122, when combined with Lucentis, did not meet the trial's main goal of improving visual acuity in patients with wet AMD compared to those taking Lucentis alone.
Lead Product(s): Carotuximab
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
